MW 2000 Da for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Protected from light,Store at -20°C,Argon charged Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 2 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) conjugated Polyethylene Glycol, DSPE PEG is a phospholipid PEG conjugate which has both hydrophilicity and hydrophobility. Pegylated phospholipids are excellent liposome formation materials that can be used for drug delivery, gene transfection and vaccine delivery as well. Pegylation of phospholipids significantly improves the blood circulation time and stability for encapsulated drugs. These materials can also be used for targeted drug delivery by modifying their surfaces with targeting ligands such as antibodies, peptides.
| Pubchem Sid | 504772981 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504772981 |
| Isomeric SMILES | CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC(=O)OCCO)OC(=O)CCCCCCCCCCCCCCCCC |
| PubChem CID | 122632359 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 D2621210 | Certificate of Analysis | Mar 30, 2026 | D163614 |
| D2621208 | Certificate of Analysis | Mar 30, 2026 | D163614 |
| I2209170 | Certificate of Analysis | Mar 11, 2026 | D163614 |
| F2527393 | Certificate of Analysis | Jun 12, 2025 | D163614 |
| F2527392 | Certificate of Analysis | Jun 12, 2025 | D163614 |
| B2513349 | Certificate of Analysis | Feb 06, 2025 | D163614 |
| B2513348 | Certificate of Analysis | Feb 06, 2025 | D163614 |
| D2303847 | Certificate of Analysis | Jan 07, 2025 | D163614 |
| D2303845 | Certificate of Analysis | Jan 07, 2025 | D163614 |
| I2209177 | Certificate of Analysis | Jun 15, 2024 | D163614 |
| G2116159 | Certificate of Analysis | Apr 07, 2024 | D163614 |
| G2116157 | Certificate of Analysis | Apr 07, 2024 | D163614 |
| I2022172 | Certificate of Analysis | Jul 14, 2023 | D163614 |
| D2303831 | Certificate of Analysis | Dec 19, 2022 | D163614 |
| D2303829 | Certificate of Analysis | Dec 19, 2022 | D163614 |
| I2212029 | Certificate of Analysis | Jun 27, 2022 | D163614 |
| I2212030 | Certificate of Analysis | Jun 27, 2022 | D163614 |
| Sensitivity | Light sensitive；Moisture sensitive |
|---|
| 1. Li Xinyang, Ding Binbin, Li Jing, Han Di, Chen Hao, Tan Jia, Meng Qi, Zheng Pan, Ma Ping’an, Lin Jun. (2024) Valence-tailored copper-based nanoparticles for enhanced chemodynamic therapy through prolonged ROS generation and potentiated GSH depletion. Nano Research, [PMID:] [10.1007/s12274-024-6552-2] |
| 2. Ting-Ting Hu, Ying Ding, Yi-Ren Yao, Xin Zhang, Xi-Wen Zhang, Yang Gu. (2026) Erythrocyte membrane-camouflaged doxorubicin nanoparticles for enhancing therapeutic efficacy in primary liver cancer. JOURNAL OF DRUG TARGETING, [PMID:] [10.1080/1061186X.2026.2647068] |
